Adjuvant chemotherapy decision-making in stage II colon adenocarcinoma associated with patients ’ age and high-risk factors
ConclusionAge and HRFs could be preferable for determining the group of stage II colon adenocarcinoma patients who would benefit from AC. Patients aged < 50 years with two or more HRFs might be a potential benefit population for AC.
Source: International Journal of Colorectal Disease - Category: Gastroenterology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Colon Cancer | Colorectal Cancer | Databases & Libraries | Epidemiology | Gastroenterology | Study